(Q34081364)

30 July 2017

title

Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study (English)

1 reference

30 July 2017

0 references

0 references

1 reference

1 reference

21

Jeffrey R Curtis

1 reference

30 July 2017

11

Carlos G Grijalva

1 reference

30 July 2017

20

Daniel H Solomon

1 reference

30 July 2017

19

James D Lewis

1 reference

30 July 2017

1

Kevin L Winthrop

1 reference

30 July 2017

12

Elizabeth Delzell

1 reference

30 July 2017

18

Kenneth G Saag

1 reference

30 July 2017

13

Timothy Beukelman

1 reference

30 July 2017

16

Lisa J Herrinton

1 reference

30 July 2017

Lang Chen

2

1 reference

30 July 2017

Frederick W Fraunfelder

3

1 reference

30 July 2017

Jennifer H Ku

4

1 reference

30 July 2017

Cara D Varley

5

1 reference

30 July 2017

Eric Suhler

6

1 reference

30 July 2017

William L Hills

7

1 reference

30 July 2017

Devin Gattey

8

1 reference

30 July 2017

John W Baddley

9

1 reference

30 July 2017

Liyan Liu

10

1 reference

30 July 2017

Nivedita M Patkar

14

1 reference

30 July 2017

Fenglong Xie

15

1 reference

30 July 2017

Fritz T Fraunfelder

17

1 reference

30 July 2017

language of work or name

English

0 references

publication date

8 September 2012

1 reference

American Journal of Ophthalmology

30 July 2017

published in

1 reference

30 July 2017

volume

155

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

183-189.e1

1 reference

Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Optic neuritis occurring with anti-tumour necrosis factor alpha therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Performance of a rheumatoid arthritis records-based index of severity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Optic neuritis: A population-based study in Olrnsted County, Minnesota

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4142597

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22967869

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22967869

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.AJO.2012.06.023

1 reference

30 July 2017

1 reference

30 July 2017

1 reference